ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

KALV KalVista Pharmaceuticals Inc

11.855
0.785 (7.09%)
Last Updated: 15:49:48
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,968,789
Bid Price 11.84
Ask Price 11.87
News -
Day High 12.4555

Low
6.60

52 Week Range

High
16.88

Day Low 10.92
Company Name Stock Ticker Symbol Market Type
KalVista Pharmaceuticals Inc KALV NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.785 7.09% 11.855 15:49:48
Open Price Low Price High Price Close Price Prev Close
11.08 10.92 12.4555 11.07
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
13,294 1,968,789 $ 11.80 $ 23,226,457 - 6.60 - 16.88
Last Trade Time Type Quantity Stock Price Currency
15:49:56 100 $ 11.855 USD

KalVista Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
502.46M 42.19M - 0 -92.91M -2.20 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

KalVista Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No KALV Message Board. Create One! See More Posts on KALV Message Board See More Message Board Posts

Historical KALV Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week12.3012.7010.7011.38370,305-0.445-3.62%
1 Month13.5814.6210.7012.95554,244-1.73-12.70%
3 Months12.1316.8810.7013.89804,123-0.275-2.27%
6 Months9.8416.887.2112.43553,8202.0220.48%
1 Year6.6316.886.6011.67385,1905.2378.81%
3 Years28.0130.704.1212.60313,530-16.16-57.68%
5 Years28.2645.004.1216.71281,542-16.41-58.05%

KalVista Pharmaceuticals Description

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

Your Recent History

Delayed Upgrade Clock